In children aged 6–12 with progressive myopia and no history of glaucoma, ocular inflammation, or anticholinergic allergy, how does low‑dose atropine (0.01 % nightly) compare to Miyosmart peripheral‑defocus soft contact lenses for myopia control, and when should each be used?

Atropine vs Miyosmart for Myopia Control

Start with low-dose atropine 0.01% nightly as first-line therapy for progressive myopia in children aged 6–12, and consider escalating to 0.025–0.05% if progression exceeds -0.25 D over 6 months; reserve Miyosmart (DIMS/HAL spectacles) for children who cannot tolerate atropine or prefer non-pharmacologic options, though atropine demonstrates superior efficacy.

Evidence-Based Rationale

The 2023 American Academy of Ophthalmology Refractive Errors Preferred Practice Pattern establishes that muscarinic antagonists like atropine are the most effective interventions for myopia control, followed by specially designed contact lenses 1. A network meta-analysis of 30 randomized controlled trials involving 5,422 eyes confirmed this hierarchy of effectiveness 1.

Atropine: The Superior Option

Atropine demonstrates dose-dependent efficacy with an optimal balance at 0.05%, which the LAMP study showed provides double the efficacy of 0.01% atropine in slowing myopia progression 1. However, starting with 0.01% minimizes side effects while maintaining meaningful benefit.

Key efficacy data:

• 0.01% atropine reduces progression by approximately 0.22 D and axial elongation by 0.14 mm annually compared to placebo 2
• 0.05% atropine achieves mean 3-year progression of only -0.75 D versus -2.14 D in controls 3
• The LAMP trial demonstrated sustained benefit continuing into year 3 1

Critical advantage: Lower concentrations (0.01%) produce minimal rebound effect upon cessation, whereas 0.5% atropine shows significant myopic rebound 1. This makes low-dose atropine safer for long-term use.

Miyosmart/DIMS Spectacles: The Alternative

While novel spectacle lens designs with peripheral defocus (like Miyosmart/DIMS) show efficacy, they rank second to atropine in effectiveness 1. The 2023 guidelines note these are "in early stages of study and regulatory oversight" 1.

Real-world comparative data shows DIMS/HAL spectacles achieve 3-year progression of -1.31 D—significantly better than controls (-2.14 D) but inferior to 0.05% atropine (-0.75 D) 3.

Practical Treatment Algorithm

Initial Treatment (Months 0-6)

• Start all eligible children on atropine 0.01% nightly in both eyes
• Monitor for photophobia, blurred vision, or allergic reactions (rare at this concentration) 1
• Measure cycloplegic refraction and axial length at baseline and 6 months

Dose Titration Strategy (Month 6 onwards)

Based on 6-month progression 4:

• Progression <-0.25 D: Continue 0.01% atropine
• Progression -0.25 to -0.375 D: Escalate to 0.025% atropine
• Progression >-0.375 D: Escalate to 0.05% atropine

This stepwise approach reduces initial progression from -0.53 D (6 months) to -0.16 D (12-18 months) in rapid progressors 4.

When to Choose Miyosmart Instead

Consider DIMS/HAL spectacles as primary therapy when:

• Contraindications to atropine exist (though rare in this age group per FDA labeling 5)
• Family refuses pharmacologic treatment despite counseling
• Significant photophobia develops even with 0.01% atropine
• Poor compliance with nightly eye drops is anticipated

Combination Therapy

Emerging evidence suggests combining 0.01% atropine with DIMS spectacles may provide additive benefit (3-year progression -1.11 D) 3, though this requires twice-daily atropine dosing 6. Reserve this approach for rapid progressors (>-1.0 D/year) who fail monotherapy escalation.

Critical Safety Considerations

Atropine side effects are concentration-dependent 1:

• 0.01%: Minimal photophobia, no accommodation issues, no bifocals needed
• 0.05%: Mild photophobia possible, accommodation preserved in most children

• 0.1%: Significant photophobia, accommodation paralysis requiring bifocals

FDA labeling cautions about systemic absorption, particularly in children under 3 years (not applicable to this 6-12 age group) 5. The most common adverse reactions are transient eye stinging and mild photophobia 5.

Long-term safety: Two-year studies show no significant retinal function changes on multifocal electroretinography 1. Benefits persist after discontinuation without significant rebound at low concentrations 1.

Common Pitfalls to Avoid

1. Undercorrection of myopia is myopigenic—always provide full optical correction alongside myopia control treatment 1

2. Don't start with 0.05% atropine—begin low and titrate based on response to minimize side effects while maintaining efficacy 7, 4

3. Monitor every 6 months minimum—progression patterns guide dose adjustments and treatment success 3, 7

4. Don't discontinue abruptly—though rebound is minimal with low-dose atropine, gradual tapering is prudent when stopping treatment 1

The evidence strongly favors atropine as first-line therapy, with DIMS spectacles serving as an effective but secondary option for specific clinical scenarios 1, 3.